Adenosine A2A Receptor Antagonists for Cancer Immunotherapy
Author:
Affiliation:
1. Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China
Funder
Ministry of Science and Technology of the People's Republic of China
Science and Technology Commission of Shanghai Municipality
National Natural Science Foundation of China
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c00237
Reference146 articles.
1. Next Generation of Immunotherapy for Melanoma
2. Comprehensive analysis of the clinical immuno-oncology landscape
3. Next generation of immune checkpoint therapy in cancer: new developments and challenges
4. Small-Molecule Targets in Immuno-Oncology
5. Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions
Cited by 56 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Research Progress on the Strategies for Crossing the Blood–Brain Barrier;Molecular Pharmaceutics;2024-09-04
2. Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists;Molecules;2024-08-14
3. Balancing G protein selectivity and efficacy in the adenosine A2A receptor;Nature Chemical Biology;2024-07-31
4. Rosmarinic acid modulates purinergic signaling and induces apoptosis in melanoma cells;Purinergic Signalling;2024-07-20
5. A novel and selective fluorescent ligand for the study of adenosine A2B receptors;Pharmacology Research & Perspectives;2024-06-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3